Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 145, Issue 5, 2009, Pages 581-597

  Gruber, Franz ^a   Mustjoki, Satu ^b,c   Porkka, Kimmo ^b,c,d  

^a UNIVERSITY OF TROMSØ   (Norway)

^b BIOMEDICUM HELSINKI   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Acute lymphoblastic leukaemia; haematopoietic stem cell transplantation; inhibitors; Philadelphia chromosome; tyrosine kinase

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ACLARUBICIN; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; BOSUTINIB; CYCLOPHOSPHAMIDE; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYCLOSPORIN A; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NILOTINIB; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; TENIPOSIDE; TIOGUANINE; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE; XL 228;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GENE MUTATION; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HUMAN; HYPOCALCEMIA; HYPONATREMIA; IMMUNOMODULATION; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASM, RESIDUAL; PHILADELPHIA CHROMOSOME; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 66149170248     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07666.x     Document Type: Review

References (94)

1. Abdelhalim, A., Barcos, M., Block, A.W., Sait, S.N., Starostik, P., Wetzler, M. Wang, E.S. (2007) Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leukaemia & Lymphoma, 48, 1053 1056. (Pubitemid 47161585)
2. Arico, M., Valsecchi, M.G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka-Schaub, G., Kamps, W., Pui, C.H. Masera, G. (2000) Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New England Journal of Medicine, 342, 998 1006. (Pubitemid 30180646)
3. Avivi, I. Goldstone, A.H. (2003) Bone marrow transplant in Ph+ ALL patients. Bone Marrow Transplantation, 31, 623 632. (Pubitemid 36553471)
4. Barnes, D.J. Melo, J.V. (2002) Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematologica, 108, 180 202. (Pubitemid 35356695)
5. Bradeen, H.A., Eide, C.A., O'Hare, T., Johnson, K.J., Willis, S.G., Lee, F.Y., Druker, B.J. Deininger, M.W. (2006) Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood, 108, 2332 2338. (Pubitemid 44497517)
6. Carpenter, P.A., Snyder, D.S., Flowers, M.E., Sanders, J.E., Gooley, T.A., Martin, P.J., Appelbaum, F.R. Radich, J.P. (2007) Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood, 109, 2791 2793. (Pubitemid 46482072)
7. Cornelissen, J.J., Carston, M., Kollman, C., King, R., Dekker, A.W., Lowenberg, B. Anasetti, C. (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood, 97, 1572 1577. (Pubitemid 32217219)
8. Cortes, J., Jabbour, E., Kantarjian, H., Yin, C.C., Shan, J., O'Brien, S., Garcia-Manero, G., Giles, F., Breeden, M., Reeves, N., Wierda, W.G. Jones, D. (2007) Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 110, 4005 4011. (Pubitemid 350248456)
9. Dai, H., Marbach, P., Lemaire, M., Hayes, M. Elmquist, W.F. (2003) Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. Journal of Pharmacology and Experimental Therapeutics, 304, 1085 1092. (Pubitemid 36254421)
10. Dai, Y., Rahmani, M., Corey, S.J., Dent, P. Grant, S. (2004) A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. Journal of Biological Chemistry, 279, 34227 34239. (Pubitemid 39318046)
11. Deininger, M.W., McGreevey, L., Willis, S., Bainbridge, T.M., Druker, B.J. Heinrich, M.C. (2004) Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia, 18, 864 871. (Pubitemid 38500206)
12. Deininger, M., Schleuning, M., Greinix, H., Sayer, H.G., Fischer, T., Martinez, J., Maziarz, R., Olavarria, E., Verdonck, L., Schaefer, K., Boque, C., Faber, E., Nagler, A., Pogliani, E., Russell, N., Volin, L., Schanz, U., Doelken, G., Kiehl, M., Fauser, A., Druker, B., Sureda, A., Iacobelli, S., Brand, R., Krahl, R., Lange, T., Hochhaus, A., Gratwohl, A., Kolb, H. Niederwieser, D. (2006) The effect of prior exposure to imatinib on transplant-related mortality. Haematologica, 91, 452 459.
13. Delannoy, A., Delabesse, E., Lheritier, V., Castaigne, S., Rigal-Huguet, F., Raffoux, E., Garban, F., Legrand, O., Bologna, S., Dubruille, V., Turlure, P., Reman, O., Delain, M., Isnard, F., Coso, D., Raby, P., Buzyn, A., Cailleres, S., Darre, S., Fohrer, C., Sonet, A., Bilhou-Nabera, C., Bene, M.C., Dombret, H., Berthaud, P. Thomas, X. (2006) Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia, 20, 1526 1532. (Pubitemid 44264094)
14. Dombret, H., Gabert, J., Boiron, J.M., Rigal-Huguet, F., Blaise, D., Thomas, X., Delannoy, A., Buzyn, A., Bilhou-Nabera, C., Cayuela, J.M., Fenaux, P., Bourhis, J.H., Fegueux, N., Charrin, C., Boucheix, C., Lheritier, V., Esperou, H., MacIntyre, E., Vernant, J.P. Fiere, D. (2002) Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood, 100, 2357 2366.
15. Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R. Talpaz, M. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101, 690 698. (Pubitemid 36077594)
16. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R. Talpaz, M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine, 344, 1038 1042. (Pubitemid 32267973)
17. Fielding, A.K. Goldstone, A.H. (2008) Allogeneic haematopoietic stem cell transplant in Philadelphia-positive acute lymphoblastic leukaemia. Bone Marrow Transplantation, 41, 447 453.
18. Fielding, A.K., Richards, S.M., Lazarus, H.M., Litzow, M.R., Luger, S.M., Marks, D.I., McMillan, A.K., Rowe, J.M., Tallman, M.S. Goldstone, A.H. (2007) Does imatinib change the outcome in Philapdelphia chromosome positive acute lymphoblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study. Blood (ASH Annual Meeting Abstracts), 110, 8.
19. Foa, R., Fazi, P., Vitale, A., Guarini, A., De Propris, M.S., Elia, L., Cimino, G., Luppi, M., Castagnola, C., Sica, S., Nieddu, R., Piersantelli, M.N., Ferrara, F., Nobile, F., Fanin, R., Martinelli, G., Mandelli, F., Meloni, G. Baccarani, M 2008) Dasatinib monotherapy as 1st line treatment of Ph acute lymphoblastic leukemia (ALL) patients: update of the GIMEMA LAL1205 study. Haematologica, 93 (s1 367 (abstract 0992).
20. Fuster, J.L., Bermudez, M., Galera, A., Llinares, M.E., Calle, D. Ortuno, F.J. (2007) Imatinib mesylate in combination with chemotherapy in four children with de novo and advanced stage Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica, 92, 1723 1724. (Pubitemid 350248262)
21. Gambacorti-Passerini, C., Barni, R., le, C.P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Formelli, F. D'Incalci, M. (2000) Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. Journal of the National Cancer Institute, 92, 1641 1650.
22. Gambacorti-Passerini, C., Cortes, J., Kantarjian, H., Kim, D., Turkina, A., Fischer, T., Cervantes, F., Agarwal, S., Hewes, B. Brummendorf, T.H 2008) Bosutinib (SKI-606) shows high tolerability and clinical activity in patients with Philadelphia chromosome positive leukemias. Haematologica, 93 (s1 160 161 (abstract 0403).
23. Giles, F.J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H. Freedman, S.J. (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood, 109, 500 502. (Pubitemid 46105945)
24. Gleissner, B., Gokbuget, N., Bartram, C.R., Janssen, B., Rieder, H., Janssen, J.W., Fonatsch, C., Heyll, A., Voliotis, D., Beck, J., Lipp, T., Munzert, G., Maurer, J., Hoelzer, D. Thiel, E. (2002) Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood, 99, 1536 1543. (Pubitemid 34533023)
25. Goldstone, A.H., Richards, S.M., Lazarus, H.M., Tallman, M.S., Buck, G., Fielding, A.K., Burnett, A.K., Chopra, R., Wiernik, P.H., Foroni, L., Paietta, E., Litzow, M.R., Marks, D.I., Durrant, J., McMillan, A., Franklin, I.M., Luger, S., Ciobanu, N. Rowe, J.M. (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 111, 1827 1833.
26. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876 880. (Pubitemid 32743979)
27. Hofmann, W.K., Komor, M., Hoelzer, D. Ottmann, O.G. (2004) Mechanisms of resistance to STI571 (Imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leukaemia & Lymphoma, 45, 655 660. (Pubitemid 38256025)
28. Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R.A. Li, S. (2004) Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nature Genetics, 36, 453 461. (Pubitemid 38620028)
29. Hu, Y., Swerdlow, S., Duffy, T.M., Weinmann, R., Lee, F.Y. Li, S. (2006) Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America, 103, 16870 16875.
30. Hughes, T.P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M.L., Gathmann, I., Bolton, A.E., van, H.I, Goldman, J.M. Radich, J.P. (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 349, 1423 1432. (Pubitemid 37211057)
31. Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Baccarani, M., Cortes, J., Cross, N.C., Druker, B.J., Gabert, J., Grimwade, D., Hehlmann, R., Kamel-Reid, S., Lipton, J.H., Longtine, J., Martinelli, G., Saglio, G., Soverini, S., Stock, W. Goldman, J.M. (2006) Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 108, 28 37. (Pubitemid 43990609)
32. Iacobucci, I., Lonetti, A., Messa, F., Cilloni, D., Arruga, F., Ottaviani, E., Paolini, S., Papayannidis, C., Piccaluga, P.P., Giannoulia, P., Soverini, S., Amabile, M., Poerio, A., Saglio, G., Pane, F., Berton, G., Baruzzi, A., Vitale, A., Chiaretti, S., Perini, G., Foa, R., Baccarani, M. Martinelli, G. (2008) Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood, 112, 3847 3855.
33. Iida, H., Sao, H., Kitaori, K., Gotoh, S., Yazaki, M., Kojima, S., Wakita, A., Morishima, Y., Kodera, Y. Morishita, Y. (2004) Twenty years' experience in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in the Nagoya Blood and Marrow Transplantation Group. International Journal of Hematology, 79, 79 84. (Pubitemid 38182206)
34. Illmer, T., Schaich, M., Platzbecker, U., Freiberg-Richter, J., Oelschlagel, U., von, B.M., Pursche, S., Bergemann, T., Ehninger, G. Schleyer, E. (2004) P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia, 18, 401 408. (Pubitemid 38425851)
35. Jones, D., Thomas, D., Yin, C.C., O'Brien, S., Cortes, J.E., Jabbour, E., Breeden, M., Giles, F.J., Zhao, W. Kantarjian, H.M. (2008) Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer, 113, 985 994.
36. Kang, H.Y., Hwang, J.Y., Kim, S.H., Goh, H.G., Kim, M. Kim, D.W. (2006) Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Haematologica, 91, 659 662. (Pubitemid 43799464)
37. Kantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso-Ramos, C.E., Pierce, S., Shan, J., Koller, C., Beran, M., Keating, M. Freireich, E.J. (2004) Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer, 101, 2788 2801. (Pubitemid 39603187)
38. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., Bochinski, K., Hochhaus, A., Griffin, J.D., Hoelzer, D., Albitar, M., Dugan, M., Cortes, J., Alland, L. Ottmann, O.G. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine, 354, 2542 2551. (Pubitemid 43882350)
39. Kantarjian, H.M., Cortes, J., le Coutre, P., Nagler, A., Pinilla, J., Hochhaus, A., Jones, D., Craig, A.R., Carroll, E. Ottmann, O.G 2007) A phase I study of INNO-406 in patients with advanced Philadelphia (Ph+) chromosome-positive leukemias who are resistant or intolerant to imatinib and second generation tyrosine kinase inhibitors. Blood (ASH Annual Meeting Abstracts), 110, 144a (abstract 469).
40. Khorashad, J.S., Milojkovic, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A.G., De, M. V, Babb, A., de, L.H., Olavarria, E., Marin, D., Goldman, J.M., Apperley, J.F. Kaeda, J.S. (2008) In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood, 111, 2378 2381.
41. Kurzrock, R., Kantarjian, H.M., Druker, B.J. Talpaz, M. (2003) Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Annals of Internal Medicine, 138, 819 830. (Pubitemid 38124644)
42. de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Rea, D., Cayuela, J.M., Vekemans, M.C., Reman, O., Buzyn, A., Pigneux, A., Escoffre, M., Chalandon, Y., MacIntyre, E., Lheritier, V., Vernant, J.P., Thomas, X., Ifrah, N. Dombret, H. (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood, 109, 1408 1413. (Pubitemid 46239571)
43. Laport, G.G., Alvarnas, J.C., Palmer, J.M., Snyder, D.S., Slovak, M.L., Cherry, A.M., Wong, R.M., Negrin, R.S., Blume, K.G. Forman, S.J. (2008) Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood, 112, 903 909.
44. Lee, S., Kim, Y.J., Min, C.K., Kim, H.J., Eom, K.S., Kim, D.W., Lee, J.W., Min, W.S. Kim, C.C. (2005) The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood, 105, 3449 3457. (Pubitemid 40628185)
45. Lee, S., Kim, Y.J., Min, C.K., Cho, B.S., Kim, S.Y., Eom, K.S., Kim, H., Cho, S.G., Kim, D.W., Lee, J.W., Min, W.S. Kim, C.C 2007) Predictive potential of minimal residual disease level after the first imatinib cycle on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts), 110, 333a (abstract 1098)
46. Lombardo, L.J., Lee, F.Y., Chen, P., Norris, D., Barrish, J.C., Behnia, K., Castaneda, S., Cornelius, L.A., Das, J., Doweyko, A.M., Fairchild, C., Hunt, J.T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G.L., Schmidt, R.J., Tokarski, J., Wen, M.L., Wityak, J. Borzilleri, R.M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry, 47, 6658 6661. (Pubitemid 40053752)
47. Mishra, S., Zhang, B., Cunnick, J.M., Heisterkamp, N. Groffen, J. (2006) Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells. Cancer Research, 66, 5387 5393. (Pubitemid 43844965)
48. Miyamura, K., Tanimoto, M., Morishima, Y., Horibe, K., Yamamoto, K., Akatsuka, M., Kodera, Y., Kojima, S., Matsuyama, K., Hirabayashi, N., Yazaki, M, Imai, K, Onozawa, Y, Kanamaru, A, Mizutani, S Saito, H. (1992) Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation. Blood, 79, 1366 1370.
49. Mohty, M., Labopin, M., Tabrizzi, R., Theorin, N., Fauser, A.A., Rambaldi, A., Maertens, J., Slavin, S., Majolino, I., Nagler, A., Blaise, D. Rocha, V., on behalf of the Acute Leukemia Working Party 2008) Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica, 93, 303 306.
50. Moorman, A.V., Harrison, C.J., Buck, G.A., Richards, S.M., Secker-Walker, L.M., Martineau, M., Vance, G.H., Cherry, A.M., Higgins, R.R., Fielding, A.K., Foroni, L., Paietta, E., Tallman, M.S., Litzow, M.R., Wiernik, P.H., Rowe, J.M., Goldstone, A.H. Dewald, G.W. (2007) Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood, 109, 3189 3197. (Pubitemid 46572503)
51. Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.H., Relling, M.V., Shurtleff, S.A. Downing, J.R. (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453, 110 114.
52. Mustjoki, S., Ekblom, M., Arstila, T.P., Dybedal, I., Epling-Burnette, P.K., Guilhot, F., Hjorth-Hansen, H., Höglund, M., Kovanen, P., Laurinolli, T., Liesveld, J., Paquette, R., Pinilla-Ibarz, J., Rauhala, A., Shah, N., Simonsson, B., Sinisalo, M., Steegmann, J.L., Stenke, L. Porkka, K. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia, doi :.
53. Nam, S., Kim, D., Cheng, J.Q., Zhang, S., Lee, J.H., Buettner, R., Mirosevich, J., Lee, F.Y. Jove, R. (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Research, 65, 9185 9189. (Pubitemid 41507982)
54. O'Hare, T., Walters, D.K., Stoffregen, E.P., Jia, T., Manley, P.W., Mestan, J., Cowan-Jacob, S.W., Lee, F.Y., Heinrich, M.C., Deininger, M.W. Druker, B.J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research, 65, 4500 4505. (Pubitemid 40740783)
55. Ottmann, O.G., Druker, B.J., Sawyers, C.L., Goldman, J.M., Reiffers, J., Silver, R.T., Tura, S., Fischer, T., Deininger, M.W., Schiffer, C.A., Baccarani, M., Gratwohl, A., Hochhaus, A., Hoelzer, D., Fernandes-Reese, S., Gathmann, I., Capdeville, R. O'Brien, S.G. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood, 100, 1965 1971.
56. Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R.A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A.M., Gollerkeri, A. Coutre, S. (2007a) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a Phase II study. Blood, 110, 2309 2315. (Pubitemid 47523149)
57. Ottmann, O.G., Wassmann, B., Pfeifer, H., Giagounidis, A., Stelljes, M., Duhrsen, U., Schmalzing, M., Wunderle, L., Binckebanck, A. Hoelzer, D. (2007b) Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer, 109, 2068 2076. (Pubitemid 46745234)
58. Ottmann, O.G., Larson, R.A., Kantarjian, H.M., le Coutre, P., Baccarani, M., Haque, A., Gallagher, N. Giles, F. (2007c) Nilotinib in patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia who are resistant or intolerant to imatinib. Blood (ASH Annual Meeting Abstracts), 110, 2815.
59. Petzer, A.L., Gunsilius, E., Hayes, M., Stockhammer, G., Duba, H.C., Schneller, F., Grunewald, K., Poewe, W. Gastl, G. (2002) Low concentrations of STI571 in the cerebrospinal fluid: a case report. British Journal of Haematology, 117, 623 625. (Pubitemid 34546037)
60. Pfeifer, H., Wassmann, B., Hofmann, W.K., Komor, M., Scheuring, U., Bruck, P., Binckebanck, A., Schleyer, E., Gokbuget, N., Wolff, T., Lubbert, M., Leimer, L., Gschaidmeier, H., Hoelzer, D. Ottmann, O.G. (2003) Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical Cancer Research, 9, 4674 4681. (Pubitemid 37336441)
61. Pfeifer, H., Wassmann, B., Pavlova, A., Wunderle, L., Oldenburg, J., Binckebanck, A., Lange, T., Hochhaus, A., Wystub, S., Bruck, P., Hoelzer, D. Ottmann, O.G. (2007a) Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 110, 727 734.
62. Pfeifer, H., Wassmann, B., Wystub, S., Brueck, P., Hochhaus, A., Serve, H., Hoelzer, D. Ottmann, O 2007b) More rapid outgrowth kinetics of BCR-ABL mutations in advanced versus newly diagnosed Philadelphia-positive acute lymphoblastic leukemia: clinical-translational evidence for a contributory role of non-mutational resistance mechanisms. Blood (ASH Annual Meeting Abstracts), 110, 11a (abstract 10).
63. Porkka, K., Martinelli, G., Ottman, O.G., Dombret, H., Garzon, F.T., Zhu, C., Larson, R.A. Simonsson, B 2008a) Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Haematologica, 93 (s1 1 (abstract 0001).
64. Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S., Smykla, R., Wild, R., Luo, R., Arnan, M., Brethon, B., Eccersley, L., Hjorth-Hansen, H., Hoglund, M., Klamova, H., Knutsen, H., Parikh, S., Raffoux, E., Gruber, F., Brito-Babapulle, F., Dombret, H., Duarte, R.F., Elonen, E., Paquette, R., Zwaan, C.M. Lee, F.Y. (2008b) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112, 1005 1012.
65. Preudhomme, C., Henic, N., Cazin, B., Lai, J.L., Bertheas, M.F., Vanrumbeke, M., Lemoine, F., Jouet, J.P., Deconninck, E., Nelken, B., Cosson, A. Fenaux, P. (1997) Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL). Leukemia, 11, 294 298. (Pubitemid 27085176)
66. Pui, C.H., Relling, M.V. Downing, J.R. (2004) Acute lymphoblastic leukemia. New England Journal of Medicine, 350, 1535 1548.
67. Radich, J., Gehly, G., Lee, A., Avery, R., Bryant, E., Edmands, S., Gooley, T., Kessler, P., Kirk, J., Ladne, P., Thomas, E.D. Appelbaum, F.R. (1997) Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood, 89, 2602 2609. (Pubitemid 27143311)
68. Ravandi, F., Faderl, S., Thomas, D.A., Brown, D., Garris, R., Borthakur, G., Ferrajoli, A., Cortes, J.E., Kantarjian, H.M. O'Brien, S.M 2008) Phase II study of combination of the hyperCVAD regimen with dasatinib in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Journal of Clinical Oncology (ASCO Meeting Abstracts), 26 (May 20 suppl 377s (abstract 7020).
69. Schultz, K.R., Bowman, W.P., Slayton, W., Aledo, A., Devidas, M., Sather, H., Borowitz, M.J., Davies, S.M., Trigg, M., Pasut, B., Jorstad, D., Eslinger, T., Burden, L.E., Wang, C., Rutledge, R., Gaynon, P.S., Carroll, A.J., Heerema, N.A., Winick, N., Hunger, S., Carroll, W.L. Camitta, B. (2007) Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) study AALL0031. Blood (ASH Annual Meeting Abstracts), 110, 4.
70. Secker-Walker, L.M., Craig, J.M., Hawkins, J.M. Hoffbrand, A.V. (1991) Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia, 5, 196 199.
71. Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D. Sawyers, C.L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, 399 401. (Pubitemid 38938156)
72. Shah, N.P., Skaggs, B.J., Branford, S., Hughes, T.P., Nicoll, J.M., Paquette, R.L. Sawyers, C.L. (2007) Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. Journal of Clinical Investigation, 117, 2562 2569. (Pubitemid 47494357)
73. Shah, P., Asatiani, E., Cortes, J., Paquette, R.L., Pinilla-Ibarz, J., Kasap, C., Bui, L.A., Yaron, Y., Clary, D.O. Talpaz, M. (2008) Interim results from a phase I clinical trial of the BCR-ABL inhibitor XL228 in drug-resistant Ph+ leukemias. Haematologica, 93, 47 48.
74. Soverini, S., Martinelli, G., Amabile, M., Poerio, A., Bianchini, M., Rosti, G., Pane, F., Saglio, G. Baccarani, M. (2004) Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clinical Chemistry, 50, 1205 1213. (Pubitemid 38824229)
75. Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P.P., Palandri, F., Giannoulia, P., Marzocchi, G., Luatti, S., Testoni, N., Iacobucci, I., Cilloni, D., Saglio, G., Baccarani, M. Martinelli, G. (2007) Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 92, 401 404. (Pubitemid 350143551)
76. Stirewalt, D.L., Guthrie, K.A., Beppu, L., Bryant, E.M., Doney, K., Gooley, T., Appelbaum, F.R. Radich, J.P. (2003) Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biology of Blood and Marrow Transplantation, 9, 206 212.
77. Takayama, N., Sato, N., O'Brien, S.G., Ikeda, Y. Okamoto, S. (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. British Journal of Haematology, 119, 106 108. (Pubitemid 35176504)
78. Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M.A., Iyer, V., Chen, T.T., Huang, F., Decillis, A.P. Sawyers, C.L. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 2531 2541. (Pubitemid 43882349)
79. Thomas, D.A., Faderl, S., Cortes, J., O'Brien, S., Giles, F.J., Kornblau, S.M., Garcia-Manero, G., Keating, M.J., Andreeff, M., Jeha, S., Beran, M., Verstovsek, S., Pierce, S., Letvak, L., Salvado, A., Champlin, R., Talpaz, M. Kantarjian, H. (2004) Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood, 103, 4396 4407. (Pubitemid 38745962)
80. Thomas, D.A., Kantarjian, H.M., Cortes, J.E., Ravandi, F., Faderl, S., Jones, D., Letvak, L., Champlin, R.E. O'Brien, S.M. (2008) Outcome after frontline therapy with the hyper-CVAD and imatinib mesylate regimen for adults with de novo or minimally treated Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology (ASCO Annual Meeting Proceedings), 26, 7019.
81. Tokarski, J.S., Newitt, J.A., Chang, C.Y., Cheng, J.D., Wittekind, M., Kiefer, S.E., Kish, K., Lee, F.Y., Borzillerri, R., Lombardo, L.J., Xie, D., Zhang, Y. Klei, H.E. (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Research, 66, 5790 5797. (Pubitemid 43927133)
82. Uckun, F.M., Nachman, J.B., Sather, H.N., Sensel, M.G., Kraft, P., Steinherz, P.G., Lange, B., Hutchinson, R., Reaman, G.H., Gaynon, P.S. Heerema, N.A. (1998) Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group. Cancer, 83, 2030 2039. (Pubitemid 28503737)
83. Vignetti, M., Fazi, P., Cimino, G., Martinelli, G., Di, R.F., Ferrara, F., Meloni, G., Ambrosetti, A., Quarta, G., Pagano, L., Rege-Cambrin, G., Elia, L., Bertieri, R., Annino, L., Foa, R., Baccarani, M. Mandelli, F. (2007) Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive acute lymphoblastic leukemia patients without additional chemotherapy: results of the GIMEMA LAL0201-B protocol. Blood, 109, 3676 3678. (Pubitemid 46641715)
84. Wassmann, B., Pfeifer, H., Stadler, M., Bornhauser, M., Bug, G., Scheuring, U.J., Bruck, P., Stelljes, M., Schwerdtfeger, R., Basara, N., Perz, J., Bunjes, D., Ledderose, G., Mahlberg, R., Binckebanck, A., Gschaidmeier, H., Hoelzer, D. Ottmann, O.G. (2005) Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 106, 458 463. (Pubitemid 40981238)
85. Wassmann, B., Pfeifer, H., Goekbuget, N., Beelen, D.W., Beck, J., Stelljes, M., Bornhauser, M., Reichle, A., Perz, J., Haas, R., Ganser, A., Schmid, M., Kanz, L., Lenz, G., Kaufmann, M., Binckebanck, A., Bruck, P., Reutzel, R., Gschaidmeier, H., Schwartz, S., Hoelzer, D. Ottmann, O.G. (2006) Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood, 108, 1469 1477. (Pubitemid 44316110)
86. Weisberg, E., Manley, P.W., Breitenstein, W., Bruggen, J., Cowan-Jacob, S.W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., Kung, A.L., Mestan, J., Daley, G.Q., Callahan, L., Catley, L., Cavazza, C., Azam, M., Neuberg, D., Wright, R.D., Gilliland, D.G. Griffin, J.D. (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell, 7, 129 141. (Pubitemid 40248339)
87. Willis, S.G., Lange, T., Demehri, S., Otto, S., Crossman, L., Niederwieser, D., Stoffregen, E.P., McWeeney, S., Kovacs, I., Park, B., Druker, B.J. Deininger, M.W. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood, 106, 2128 2137. (Pubitemid 41291730)
88. Wu, J., Meng, F., Kong, L.Y., Peng, Z., Ying, Y., Bornmann, W.G., Darnay, B.G., Lamothe, B., Sun, H., Talpaz, M. Donato, N.J. (2008a) Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. Journal of the National Cancer Institute, 100, 926 939.
89. Wu, J., Meng, F., Lu, H., Kong, L., Bornmann, W., Peng, Z., Talpaz, M. Donato, N.J. (2008b) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. Blood, 111, 3821 3829.
90. Yanada, M., Naoe, T., Iida, H., Sakamaki, H., Sakura, T., Kanamori, H., Kodera, Y., Okamoto, S., Kanda, Y., Sao, H., Asai, O., Nakai, K., Maruta, A., Kishi, K., Furukawa, T., Atsuta, Y., Yamamoto, K., Tanaka, J. Takahashi, S. (2005) Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplantation, 36, 867 872. (Pubitemid 41655612)
91. Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Kobayashi, T., Ueda, Y., Takeuchi, M., Miyawaki, S., Maruta, A., Emi, N., Miyazaki, Y., Ohtake, S., Jinnai, I., Matsuo, K., Naoe, T. Ohno, R. (2006) High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. Journal of Clinical Oncology, 24, 460 466. (Pubitemid 46630465)
92. Yanada, M., Takeuchi, J., Sugiura, I., Akiyama, H., Usui, N., Yagasaki, F., Nishii, K., Ueda, Y., Takeuchi, M., Miyawaki, S., Maruta, A., Narimatsu, H., Miyazaki, Y., Ohtake, S., Jinnai, I., Matsuo, K., Naoe, T. Ohno, R. (2008) Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica, 93, 287 290.
93. Yokota, A., Kimura, S., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., Terui, Y., Ruthardt, M., Ueda, T., Hatake, K., Inui, K. Maekawa, T. (2007) INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 109, 306 314. (Pubitemid 46053071)
94. Zwaan, C.M., Kearns, P., Den Boerd, M.L., Beverloo, H.B., Van der Velden, V.H.J., Van Tornout, J.M.A., Derreumaux, D., Lehrnbecher, T., Mechinaud, F., Rizzari, C., Baruchel, A. Pieters, R 2008) Dasatinib in children and adolescents with relapsed or refractory leukemia: Preliminary results of the CA180018 Phase I/II study from the ITCC consortium. Haematologica, 93 (s1 367 368 (abstract 0923).